Inside MedSpa — Never miss a recall or a rule change.
InMode Q2 Beats EPS Forecast, Revenue Tops Estimates
FDA Accepts BOTOX Masseter sBLA—Jawline Approval Path Clear
Daewoong's NABOTA Enters Seventh Middle East Market
Hugel Posts Record H1 Earnings on Toxin Growth
InMode Q2 Revenue Beats Estimates at $95.6M
The Brief
What just changed for your practiceEvolus Q2 profitability and guidance raise signal market share pressure on AbbVie
Evolus reported Q2 2026 revenue of $84.1M (21% YoY growth), third consecutive quarter of positive adjusted EBITDA, and raised full-year guidance. The company is aggressively marketing Jeuveau through its Evolus Rewards loyalty program to medspas.
Why it matters — Evolus's sustained profitability and accelerating revenue growth—combined with direct-to-medspa rebate competition via Evolus Rewards—signals the neuromodulator market is fragmenting. AbbVie's Botox/Juvéderm duopoly faces real margin pressure. Owners using Evolus products now have leverage to negotiate better Allē terms with AbbVie, or face defection risk. The loyalty-program arms race is real: rebate structures are shifting without announcement (see item [20]), and your per-unit economics depend on which manufacturer you're locked into.
FDA accepts Botox Cosmetic supplemental application for masseter muscle prominence
The FDA accepted AbbVie's supplemental biologics license application (sBLA) for Botox Cosmetic in the masseter muscle for jaw contouring. This is a new indication beyond the existing cosmetic approvals.
InMode Q2 beats revenue estimates; energy-device demand remains steady
InMode reported Q2 2026 revenue of $95.6M, beating FactSet estimates of $93.1M, with EPS beat of $0.02. U.S. demand for RF microneedling and other energy modalities remained solid.
Evolus Rewards program terms changed; review your rebate structure immediately
The Evolus Rewards program page was updated with new terms, indicating a shift in manufacturer loyalty and rebate structure. No formal announcement was made.
Devices & Tech
Sofwave Q2 Revenue Accelerates on Ultrasonic Demand
Ultrasonic microneedling platform drives second-quarter growth for the device maker.
Compliance
Evolus Rewards Program Terms Changed—Review Now
Manufacturer loyalty program updated; injectors must verify rebate impact on unit economics.
Business & M&A
AbbVie Files Material Event—Allē Rebate Terms Shifting
Botox and Juvéderm loyalty program changes signal margin pressure across the injector base.
Business & M&A
Evolus Files Material Event—Jeuveau Pricing Escalates
Aggressive Evolus Rewards program targeting medspas signals toxin price wars are live.
Devices & Tech
InMode Q2 Revenue Beats on Steady U.S. Device Demand
Q2 revenue of $95.6M exceeds FactSet estimate; U.S. market remains resilient.
Regulatory
AbbVie Wins FDA Review for BOTOX Jawline Indication
Supplemental BLA accepted; masseter prominence treatment moves closer to approval.
Business & M&A
Evolus Posts Third Straight Profitable Quarter, Raises Outlook
Revenue growth accelerates; adjusted EBITDA positive for third consecutive quarter.
Devices & Tech
InMode Q2 Beats on Steady U.S. Device Demand
Earnings topped estimates; U.S. market holding despite competitive RF microneedling saturation.
Devices & Tech
Sofwave Q2 Revenue Accelerates on Ultrasonic Demand
Ultrasonic RF microneedling platform shows strong uptake; company reports Q2 and H1 results.
Get a free FDA recall alert when a product you use is pulled.
We'll email you the moment a product you inject gets recalled or your state changes who's allowed to inject — plus a free 50-state “who can inject” cheat-sheet. No spam, unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Primary sources. No agenda. Verified before it runs.
Good-Faith Exam Requirements by State (incl. Telehealth)
What constitutes a valid good-faith exam, who can perform it, and how state telehealth rules reshape compliance for remote consultations.
TrackerMedspa Marketing Channel Benchmarks & CAC
Where efficient patient acquisition lives in aesthetics: channel-by-channel CAC data, conversion patterns, and the math that separates profitable growth from cash burn.
TrackerMedspa Industry by the Numbers: Market Size & Benchmarks
The hard data owners cite: U.S. market size, clinic count and growth rates, revenue per location, GLP-1 injectable demand surge, and regulatory enforcement trends—with sources.